- Home
- PCYO vs YMAB Comparison
PCYO vs YMAB Comparison
Compare PCYO & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCYO
- YMAB
- Stock Information
- Founded
- PCYO 1976
- YMAB 2015
- Country
- PCYO United States
- YMAB United States
- Employees
- PCYO N/A
- YMAB N/A
- Industry
- PCYO Water Supply
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PCYO Utilities
- YMAB Health Care
- Exchange
- PCYO Nasdaq
- YMAB Nasdaq
- Market Cap
- PCYO 271.7M
- YMAB 270.5M
- IPO Year
- PCYO N/A
- YMAB 2018
- Fundamental
- Price
- PCYO $10.47
- YMAB $4.43
- Analyst Decision
- PCYO
- YMAB Buy
- Analyst Count
- PCYO 0
- YMAB 11
- Target Price
- PCYO N/A
- YMAB $18.73
- AVG Volume (30 Days)
- PCYO 35.0K
- YMAB 328.7K
- Earning Date
- PCYO 04-09-2025
- YMAB 03-04-2025
- Dividend Yield
- PCYO N/A
- YMAB N/A
- EPS Growth
- PCYO 103.72
- YMAB N/A
- EPS
- PCYO 0.55
- YMAB N/A
- Revenue
- PCYO $29,113,000.00
- YMAB $87,685,000.00
- Revenue This Year
- PCYO N/A
- YMAB $20.07
- Revenue Next Year
- PCYO N/A
- YMAB $8.76
- P/E Ratio
- PCYO $19.51
- YMAB N/A
- Revenue Growth
- PCYO 56.25
- YMAB 3.38
- 52 Week Low
- PCYO $8.94
- YMAB $4.25
- 52 Week High
- PCYO $14.63
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- PCYO 37.08
- YMAB 34.59
- Support Level
- PCYO $10.41
- YMAB $4.65
- Resistance Level
- PCYO $10.80
- YMAB $5.25
- Average True Range (ATR)
- PCYO 0.22
- YMAB 0.30
- MACD
- PCYO 0.02
- YMAB 0.03
- Stochastic Oscillator
- PCYO 24.56
- YMAB 6.32
About PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. It designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The company's services include water production, storage, treatment, bulk transmission to retail distribution systems, wastewater collection and treatment, irrigation water treatment and transmission, construction management, billing, and collection. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.